pentobarbital will boost the degree or outcome of clopidogrel by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Watch.
Stay away from; coadministration with CYP3A inducers may perhaps result in decreased plasma concentrations of elvitegravir and/or even a concomitantly administered protease inhibitor and cause lack of therapeutic result and also to probable resistance
pentobarbital will lower the extent or outcome of alosetron by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Slight/Importance Not known.
pentobarbital will decrease the extent or effect of nicardipine by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.
pentobarbital will lessen the level or outcome of zaleplon by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.
pentobarbital will reduce the level or influence of alosetron by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Importance Unfamiliar.
Check Carefully (three)pentobarbital will decrease the extent or impact of diazepam intranasal by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Watch. Solid or reasonable CYP3A4 inducers could boost charge of diazepam elimination; as a result, efficacy of diazepam can be diminished.
Much too speedy administration might induce respiratory despair, laryngospasm, apnea, or vasodilation with drop in blood pressure
Contraindicated (one)pentobarbital will decrease the extent or impact of lumacaftor/ivacaftor by influencing hepatic/intestinal enzyme CYP3A4 metabolism.
pentobarbital will lower the level or outcome of guanfacine by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Watch Closely. Powerful or average CYP3A4 inducers noticeably lower guanfacine plasma concentrations and elimination 50 percent-lifestyle.
pentobarbital will reduce the extent or influence of lopinavir by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Keep an eye on.
This drug may perhaps interfere While using the absorption of orally administered griseofulvin, decreasing its blood stages; consequences of blood level reduction unfamiliar; preferable to prevent concomitant administration of these medicines
Caution when discontinuing CYP3A4 inducers which might be coadministered with hydrocodone; plasma concentrations of hydrocodone may perhaps enhance and may result in probably fatal respiratory despair
Monoamine oxidase inhibitors (MAOI) could inhibit barbiturate metabolism and lengthen barbiturate effects; read more watch closely